Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

51 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Probiotic peanut oral immunotherapy versus oral immunotherapy and placebo in children with peanut allergy in Australia (PPOIT-003): a multicentre, randomised, phase 2b trial.
Loke P, Orsini F, Lozinsky AC, Gold M, O'Sullivan MD, Quinn P, Lloyd M, Ashley SE, Pitkin S, Axelrad C, Metcalfe JR, Su EL, Tey D, Robinson MN, Allen KJ, Prescott SL, Galvin AD, Tang MLK; PPOIT-003 study group. Loke P, et al. Among authors: ashley se. Lancet Child Adolesc Health. 2022 Mar;6(3):171-184. doi: 10.1016/S2352-4642(22)00006-2. Epub 2022 Feb 4. Lancet Child Adolesc Health. 2022. PMID: 35123664 Clinical Trial.
The skin barrier function gene SPINK5 is associated with challenge-proven IgE-mediated food allergy in infants.
Ashley SE, Tan HT, Vuillermin P, Dharmage SC, Tang MLK, Koplin J, Gurrin LC, Lowe A, Lodge C, Ponsonby AL, Molloy J, Martin P, Matheson MC, Saffery R, Allen KJ, Ellis JA, Martino D; HealthNuts team; Barwon Infant Study, the Melbourne Atopy Cohort study, the Peanut Allergen Threshold Study and the Probiotic and Peanut Oral ImmunoTherapy study. Ashley SE, et al. Allergy. 2017 Sep;72(9):1356-1364. doi: 10.1111/all.13143. Epub 2017 Apr 4. Allergy. 2017. PMID: 28213955
Probiotic peanut oral immunotherapy is associated with long-term persistence of 8-week sustained unresponsiveness and long-lasting quality-of-life improvement.
Loke P, Hsiao KC, Lozinsky AC, Ashley SE, Lloyd M, Pitkin S, Axelrad CJ, Jayawardana KS, Tey D, Su EL, Robinson M, Leung ASY, Dunn Galvin A, Tang MLK. Loke P, et al. Among authors: ashley se. Clin Exp Allergy. 2022 Jun;52(6):806-811. doi: 10.1111/cea.14137. Epub 2022 May 10. Clin Exp Allergy. 2022. PMID: 35485166 No abstract available.
51 results